Clinical trial
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With…
NCT00235820 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00235820 |
|---|---|
| Title | Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| Official title | A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| Acronym | CHAMPION |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | adalimumab, MTX, placebo adalimumab, placebo MTX |
| Enrollment | 271 |
| Start date | Jul 1, 2005 |
| Primary completion | May 1, 2006 |
| First posted | Oct 12, 2005 |
| Last update posted | Jul 17, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: